Sanofi Pasteur is partnering with the Biomedical Advanced Research and Development Authority (BARDA) to develop a potential vaccine for the coronavirus COVID-19 that utilizes the same recombinant DNA platform used in its influenza vaccine Flublok and in its previous vaccine candidate for severe acute respiratory syndrome (SARS).
Announcing the collaboration in a 18 February press call, David Loew, Sanofi's global head of vaccines, said leveraging this previous...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?